59 /100
HIGH RISK
Score updated Jul 14, 2026

BDRX — Biodexa Pharmaceuticals Plc Dilution Risk Tracker

Track BDRX dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track BDRX — Get alerts when the score changes →

As of July 14, 2026, Biodexa Pharmaceuticals Plc (BDRX) has a DilutionWatch DilutionScore of 59/100, rated HIGH dilution risk. Biodexa Pharmaceuticals Plc has a market capitalization of $2.59M, 225.82B shares outstanding, 8 institutional holders tracked.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
80
💰 Cash Runway
40
📊 Float Risk
0
⚠️ Warrant Exposure
40
🔄Convertible Debt

🌦️ Dilution Forecast

☀️
Clear
No significant dilution signals
0%
No significant dilution signals detected for BDRX.
🔔 Track BDRX — Get forecast alerts →

💹 Market Data

Market Cap$2.59M
Shares Outstanding225.82B
FloatN/A
Cash$11.48M
Debt$82.1K
Short InterestN/A

🏛 Institutional Holdings

8 institutional holders · 63.2K shares
#1 Sabby Management, LLC 38.1K shares
#2 Armistice Capital, LLC 20.0K shares
#3 Gamma Investing LLC 2.8K shares
+ 5 more holders Sign up free to view →

📉 Short Interest

Short Interest67.3K
Days to Cover1.0
% of FloatN/A
FINRA data as of Jun 30, 2026

📁 Recent SEC Activity

13F-HR BENEFICIAL OWNERSHIP Mar 31, 2026
13F-HR BENEFICIAL OWNERSHIP Mar 31, 2026
13F-HR BENEFICIAL OWNERSHIP Mar 31, 2026
13F-HR BENEFICIAL OWNERSHIP Mar 31, 2026
13F-HR BENEFICIAL OWNERSHIP Dec 31, 2025
Full SEC filing analysis available with free account

📰 Recent News

No recent news

📋 What This Means for BDRX Shareholders

Biodexa Pharmaceuticals Plc (BDRX) has a DilutionScore of 59/100, placing it in the High dilution risk tier. This score reflects at least one active dilution mechanism — a shelf registration, ATM program, outstanding warrants, or limited cash runway — that could materially increase the share count over the next 12–18 months. Score as of July 14, 2026, updated from SEC EDGAR data.

DilutionWatch's EDGAR monitoring for BDRX shows no major active dilution programs at this time. The primary risk categories — shelf registration capacity, ATM programs, warrant overhang, and cash runway — are each within normal ranges for a company of this profile. This can change quickly if a new S-3 or Form S-1 is filed.

DilutionWatch tracks over 25 SEC filing types for BDRX in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for BDRX alongside comparable high-risk stocks. Not financial advice — this analysis is for informational purposes only.

Track BDRX Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking BDRX — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — HIGH Risk

Other HIGH dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for BDRX
📊 BDRX FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 BDRX Signal Convergence & Dark Pool Activity — StonkWhisper 📄 BDRX Dilution Risk Analysis — Full In-Depth Report

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.